News & Events

Press Releases

April 3rd, 2019

AgomAb Therapeutics Completes €21m Series A Financing

AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.


End of content

No more pages to load

Looking to connect with us?

SVB Leerink Biopharma Private Company Connect  
October 27-29, 2021

RBC Healthcare Private Company Conference  
December 15-16, 2021


By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.